| IL01 "The dawn of the quantum SBDD era" | |||
| Chair: Taro Tamada (National Institutes for Quantum Science and Technology） | |||
| ▼IL01-01 | Koji Yonekura (RIKEN/Tohoku University） | 10/28 10:00-10:30 | |
| "Multimodal cryo-EM approaches to quantum chemical measurements" | |||
| ▼IL01-02 | Yasuteru Shigeta (Center for Computational Sciences, University of Tsukuba) | 10/28 10:30-11:00 | |
| "Computer-aided Drug Design Based on Quantum Chemical Analysis of Biomolecular Dynamics" | |||
| ▼IL01-03 | Teruki Honma (RIKEN) | 10/28 11:00-11:30 | |
| "New Horizons Opened by the Synergy of Protein Structures, AI, and the Large-Scale Quantum Chemistry Database (FMODB)" | |||
| IL02 "Diseases Genome Atlas: Pioneering a New Era of Bioinformatics" | |||
| Chair: Kentaro Tomii (AIST) | |||
| ▼IL02-01 | Seiya Imoto (the Institute of Medical Science, the University of Tokyo) | 10/29 10:00-10:30 | |
| "A New Era of Genomic Data–Driven Healthcare and Research Enabled by Whole Genome Project" | |||
| ▼IL02-02 | Hitoshi Kurumizaka (the University of Tokyo) | 10/29 10:30-11:00 | |
| "Toward Understanding Chromatin Atlases as Comprehensive Genome Regulatory Mechanisms" | |||
| ▼IL02-03 | Yukinori Okada (the University of Tokyo) | 10/29 11:00-11:30 | |
| "Statistical genetics elucidates disease biology and personalized medicine" | |||
| IL03 "Accelerating drug discovery through automated synthesis of antibodies and small molecules" | |||
| Chair: Shinichiro Fuse (Nagoya University), Midori Kamimura (CBI research Institute) |
|||
| ▼IL03-01 | Fumiaki Yumoto (Renzoku Biologics Inc.） | 10/29 14:00-14:30 | |
| "Exploring Competitive Advantages in Cost, Quality, and Speed in Antibody Manufacturing- Continuous Manufacturing as an Advanced Manufacturing Technology (AMT) -" | |||
| ▼IL03-02 | Jinki Hadano (Chugai Pharmaceutical Co., Ltd.) |
10/29 14:30-15:00 | |
| "The Evolution of Laboratory Automation for Advancing Drug‑Discovery Research" | |||
| ▼IL03-03 | Shinichiro Fuse (Nagoya University) | 10/29 15:00-15:30 | |
| "Driving drug development by utilizing flow synthesis to make the impossible possible" | |||
| Invited Talk "The dawn of the quantum SBDD era" |
[Big hall] 10/28 10:00-10:30 | |
| IL01-01 | ||
 |
Multimodal cryo-EM approaches to quantum chemical measurements | |
| Koji Yonekura | ||
| RIKEN/Tohoku University | ||
Cryo-electron microscopy (cryo-EM) comprises three major modalities: single-particle analysis, electron three-dimensional crystallography (3D ED / microED), and cryo-electron tomography (ET). These approaches collect different types of data, projection images of proteins embedded in vitreous ice, electron diffraction from small and thin crystals, and tilt series of cells and cellular organelles, to obtain three-dimensional structural information. The potential of cryo-EM–based multimodal analysis for applications in medical and drug discovery research is steadily increasing.
We have been developing analytical approaches that exploit the unique capabilities of cryo-EM. In particular, we are addressing targets that remain challenging for single-particle analysis, including small proteins, while also focusing on dynamical conformational changes and structural fluctuations. In 3D ED, we have pioneered rotation-based data collection and analysis methods since the early stages of the field, and have established an automated workflow in which electron diffraction data from numerous crystals are acquired under AI control, followed by automated data processing and structure determination. This enabled structure determination from challenging samples and has also allowed us to explore the extraction of quantum chemical information.
Furthermore, we perform in situ analyses using cryo-ET in combination with cryo-FIB-SEM, as well as microcrystal structure analysis of organic compounds using X-ray free-electron lasers (XFEL), thereby adopting an integrated approach for diverse sample forms. In this symposium, I will present these efforts and recent results, and discuss the development of quantum chemical measurements and multimodal analysis for medical and drug discovery applications, including comparisons with XFEL.
.jpg)
Rapid progress in lab automation and AI has accelerated technological innovation worldwide. Yet countries with abundant financial and human resources have taken a commanding lead, making it increasingly difficult for Japan to compete globally through individual technologies in automation or AI alone. A promising strategy for Japan is therefore to integrate these emerging tools with fields in which the nation has long maintained distinct strengths. Identifying such competitive technological domains is essential for shaping future innovation. This lecture highlights microflow synthesis, a field where Japan has sustained global competitiveness for several decades. While organic synthesis has traditionally relied on batch reactions in flasks or reactors—a framework dating back to medieval alchemy—microflow technology enables reactions to proceed within narrow channels under continuous flow. This approach provides unprecedented control over sub‑second reaction times and precise temperature regulation, conditions unachievable in conventional batch systems. As a result, microflow synthesis is now widely utilized in both academic research and industrial applications, and it offers powerful advantages for analyzing ultrafast reaction mechanisms. The lecture will particularly focus on peptide synthesis, an area gaining attention for middle‑molecule therapeutics. By combining classical reactions, known for more than half a century, with modern microflow techniques, we have achieved outcomes previously considered impossible, including orders‑of‑magnitude improvements in reaction performance.
[1] S. Fuse, Y. Mifune, T. Takahashi, Angew. Chem. Int. Ed. 2014, 53, 851.
[2] S. Fuse, Y. Mifune, H. Nakamura, H. Tanaka, Nat. Commun. 2016, 7, 13491.
[3] Y. Otake, H. Nakamura, S. Fuse, Angew. Chem. Int. Ed. 2018, 57, 11389.
[4] Y. Otake, Y. Shibata, Y. Hayashi, S. Kawauchi, H. Nakamura, S. Fuse, Angew. Chem. Int. Ed. 2020, 59, 12925.
[5] O. Shamoto, K. Komuro, N. Sugisawa, T-H. Chen, H. Nakamura, S. Fuse, Angew. Chem. Int. Ed. 2023, e202300647.
[6] N. Sugisawa, A. Ando, S. Fuse, Chem. Sci., 2023, 14, 6986.